Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.80 |
| ▸ | TYR | P14679 | 6/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278523 | 0.98 | MAPT (0.78) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL4056986 | 0.94 | MAPT (0.72) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL13788030 | 0.90 | MEN1 (0.68) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL875812 | 0.90 | MEN1 (1.00) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL875665 | 0.90 | MAPT (0.68) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL68292 | 0.89 | ALOX5 (1.00) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL29655585 | 0.89 | ALOX5 (1.00) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL29655583 | 0.89 | ALOX5 (1.00) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL51397 | 0.87 | TYR (0.71) | MAPTMEN1KMT2AALOX5TYR | |
| SCHEMBL278524 | 0.87 | MAPT (0.68) | MAPTMEN1KMT2AALOX5TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534547-B2 | Optically active compound and photosensitive resin composition | OSAKA GAS COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | MAPT 3954/4885MEN1 754/4885KMT2A 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.